Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus

Journal of Affective Disorders

Volumn 72, Issue 3, 2002, Pages 237-241

  Bonaccorso, Stefania ^a,b   Marino, Valentina ^a   Biondi, Massimo ^a   Grimaldi, Franca ^a   Ippoliti, Flora ^a   Maes, Michael ^b,c,d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Clinical Research Center for Mental Health of Antwerp   (Belgium)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d VANDERBILT UNIVERSITY   (United States)

Author keywords

Cytokine treatment; Cytokines; Depression; Immunology; Inteferon alpha

Indexed keywords

ALPHA INTERFERON;

ADULT; AGED; ANHEDONIA; ANOREXIA; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; IRRITABILITY; LONELINESS; LONG TERM CARE; MAJOR DEPRESSION; MALE; MENTAL CONCENTRATION; PRIORITY JOURNAL; PSYCHOMETRY; RATING SCALE; SIDE EFFECT; SUICIDE ATTEMPT;

AFFECT; AGED; ANTIVIRAL AGENTS; DEPRESSIVE DISORDER; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HUMANS; INCIDENCE; INTERFERON-ALPHA; MALE; MIDDLE AGED;

EID: 0036889771     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(02)00264-1     Document Type: Article

References (25)

1. Adams F., Quesada J.R., Gutterman J.U. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. J. Am. Med. Assoc. 252:1984;938-941.
2. Cavaillon J.-M. Interleukin-6. Les Cytokines. 1996;Masson, Paris.
3. Connor T.J., Leonard B.E. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci. 62:1998;583-606.
4. Dafny N., Lee J.R., Dougherty P.M. Immune response products alter CNS activity: interferon modulates central opioid function. J. Neurosci. Res. 19:1988;130-139.
5. Dafny N., Prieto-Gomez B., Dong W.-Q., Reyes-Vazquez C. Interferon modulates neuronal activity recorded from the hypothalamus, thalamus, hippocampus, amygdala and the somatosensory cortex. Brain Res. 734:1996;269-274.
6. Dusheiko G. Side effects of alpha interferon on chronic hepatitis C. Hepatology. 3:1997;121.
7. Fattovich, G., Giustina, G., Favarato, S., Ruol, A., Investigators of the Italian Association for the Study of the Liver, 1996. A survey of adverse events in 11 241 patients with chronic viral B or C hepatitis treated with alfa interferon. J. Hepatol. 38-47.
8. Hardy P. Trouble depressifs et interferon alpha. Gastroenterol. Clin. Biol. 20:1996;255-257.
9. Janssen H.L.A., Brouwer J.T., van der Mast R.C., Schalm S.W. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J. Hepatol. 21:1994;241-243.
10. Lieberman A., Pitha P.M., Shin H.S., Shin M.L. Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc. Natl. Acad. Sci. USA. 96:1989;6348-6352.
11. Maes M. The interleukin hypothesis of major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry. 19:1995;11-38.
12. Maes M. Major depression and activation of the inflammatory response system. Adv. Exp. Med. Biol. 461:1999;25-46.
13. Maes M., Smith R., Scharpe S. The monocyte-T lymphocyte hypothesis of major depression. Psychoneuroendocrinology. 20:1995;111-116.
14. Maier S.F., Watkins L.R. Cytokines for psychologists: implications of bidirectional immune-to-brain communications for understanding behavior, mood, and cognition. Psychol. Rev. 105:1998;83-107.
15. Mattson K., Niiranen A., Laaksonen R., Cantell K. Psychometric monitoring of interferon neurotoxicity. Lancet. 1:(8371):1984;275-276.
16. McDonald E.M., Mann A.H., Thomas H.C. Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers. Lancet. 21:1987;1175-1177.
17. Morikawa O., Sakai N., Obara H., Saito N. Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur. J. Pharmacol. 349:1998;317-324.
18. Pan W., Banks W.A., Kastin A.J. Permeability of blood-brain and blood-spinal cord barriers to interferons. J. Neuroimmunol. 76:1997;105-111.
19. Pavol M.A., Meyers C.A., Rexer B.S., et al. Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology. 45:1995;947-950.
20. Raber J., Koob G.F., Bloom F.E. Interferon alpha and transforming growth factor-beta-1 regulate corticotropin-releasing factor release from the amygdala: comparison with the hypothalamic response. Neurochem. Int. 30:1997;455-463.
21. Renault P.F., Hoofnagle J.H., Yoon Park R.N., Mullen K.D., Peters M., Jones B., Rustgi V., Jones A. Psychiatric complications of long-term interferon alfa therapy. Arch. Intern. Med. 147:1987;1577-1580.
22. Rifflet H., Vuillemin R.H., Oberti F., Laine P., Cales P. Interferon et suicide au cours des hepatites virales chroniques. Gastroenterol. Clin. Biol. 2:1996;68.
23. Vial T., Descotes J. Clinical toxicity of the interferons. Drug Saf. 10:1994;115-150.
24. Yamada T., Yamanaka I. Microglial localization of alpha-interferon receptor in human brain tissues. Neurosci. Lett. 189:1995;73-76.
25. Yirmiya R. Behavioral and psychological effects of immune activation: Implications for depression due to a general medical condition. Curr. Opin. Psychiatry. 10:1997;470-476.